The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
Abstract
BACKGROUND: Tenofovir (TDF) is the most widely prescribed antiretroviral drug. Kidney abnormalities are the main concern using the drug. As glomerular function is infrequently affected in patients treated with TDF, herein, we report the results of an extensive examination of tubular function. METHODS: Cross-sectional study of plasma and 24 h urine markers of kidney tubulopathy (glucosuria, hyperaminoaciduria, hyperphosphaturia, hyperuricosuria and beta2-microglobulinuria) could be allocated in three groups: patients under a TDF-containing HAART; patients on HAART never exposed to TDF; and antiretroviral-naive individuals. Significant tubular damage was defined when at least two of these parameters were repeatedly present, being at least one part of the Fanconi syndrome criteria (glucosuria, hyperaminoaciduria and hyperphosphaturia). Glomerular function was assessed using creatinine clearance. RESULTS: A total of 284 consecutive HIV patients were examined, 154 on TDF, 49 on other HAART regimens and 81 drug-naive. No significant differences in creatinine clearance were observed when comparing distinct groups. The proportion of patients with tubular damage in groups 1, 2 and 3 were 22, 6 and 12%, respectively. In a multivariate analysis [odds ratio (OR) {95% confidence interval (CI)} P], the only independent predictors of tubular dysfunction were TDF use (21.6, 4.1-113, <0.001) and older age (1.1 per year, 1.0-1.1, 0.01). CONCLUSION: Exposure to TDF is associated with an increased risk over time of kidney tubular abnormalities in the absence of significant impaired glomerular function. Although long-term consequences of this tubulopathy are unknown, close monitoring of accelerated bone mineral loss and renal insufficiency are warranted. Periodic screening of tubular function parameters should be recommended to patients receiving TDF.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Hammer, S. M., Eron, J. J., Reiss, P., Schooley, R. T., Thompson, M. A., Walmsley, S., Cahn, P., Fischl, M. A., Gatell, J. M., Hirsch, M. S., et al. (2008) · JAMA · doi:10.1001/jama.300.5.555 · Cited by 1,026
Karras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B., Lazzarin, A., Schewe, K., Lange, J., Wyatt, C., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3280b07b33 · Cited by 352
Cihlar, T., Lin, D. C., Pritchard, J. B., Fuller, M. D., Mendel, D. B., & Sweet, D. H. (1999) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)23084-4 · Cited by 345
Mechanism of Active Renal Tubular Efflux of Tenofovir
Ray, A. S., Cihlar, T., Robinson, K. L., Tong, L., Vela, J. E., Fuller, M. D., Wieman, L. M., Eisenberg, E. J., & Rhodes, G. R. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00251-06 · Cited by 323
Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428840 · Cited by 302
Goicoechea, M., Liu, S., Best, B., Sun, S., Jain, S., Kemper, C., Witt, M., Diamond, C., Haubrich, R., Louie, S., et al. (2008) · The Journal of Infectious Diseases · doi:10.1086/524061 · Cited by 299
Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases
Peyri??re, H., Reynes, J., Rouanet, I., Daniel, N., de Boever, C. M., Mauboussin, J.-M., Leray, H., Moachon, L., Vincent, D., & Salmon-C??ron, D. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00007 · Cited by 262
Association between ABCC2 Gene Haplotypes and Tenofovir‐Induced Proximal Tubulopathy
Izzedine, H., Hulot, J., Villard, E., Goyenvalle, C., Dominguez, S., Ghosn, J., Valantin, M. A., Lechat, P., & Deray, A. G. (2006) · The Journal of Infectious Diseases · doi:10.1086/508546 · Cited by 243
Drug-induced Fanconi's syndrome
Izzedine, H., Launay-Vacher, V., Isnard-Bagnis, C., & Deray, G. (2003) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50037 · Cited by 238
Arribas, J. R., Pozniak, A. L., Gallant, J. E., DeJesus, E., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Holmes, C. B., Enejosa, J., et al. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31815acab8 · Cited by 235
Khan, N. A., Hemmelgarn, B., Herman, R. J., Rabkin, S. W., McAlister, F. A., Bell, C. M., Touyz, R. M., Padwal, R., Leiter, L. A., Mahon, J. L., et al. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)70620-2 · Cited by 223
Suzuki, H., & Sugiyama, Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00075-3 · Cited by 211
Adefovir nephrotoxicity: Possible role of mitochondrial DNA depletion
Tanji, N., Tanji, K., Kambham, N., Markowitz, G. S., Bell, A., & D'Agati, V. D. (2001) · Human Pathology · doi:10.1053/hupa.2001.25586 · Cited by 207
Izzedine, H., Hulot, J. S., Vittecoq, D., Gallant, J. E., Staszewski, S., Launay-Vacher, V., Cheng, A., Deray, G., & for the Study 903 Team (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh658 · Cited by 182
Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System
Gupta, S. K. (2008) · AIDS Patient Care and STDs · doi:10.1089/apc.2007.0052 · Cited by 181
Renal safety of tenofovir in HIV treatment-experienced patients
Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004) · AIDS · doi:10.1097/00002030-200404300-00019 · Cited by 173
Bleasby, K., Hall, L. A., Perry, J. L., Mohrenweiser, H. W., & Pritchard, J. B. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084301 · Cited by 119
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure
Rifkin, B. S., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.025 · Cited by 114
Tenofovir-related nephrotoxicity in HIV-infected patients
Barrios, A., García-Benayas, T., González‐Lahoz, J., et al. (2004) · AIDS · doi:10.1097/00002030-200404090-00019 · Cited by 109
Gatanaga, H., Tachikawa, N., Kikuchi, Y., Teruya, K., Genka, I., Honda, M., Tanuma, J., Yazaki, H., Ueda, A., Kimura, S., et al. (2006) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2006.22.744 · Cited by 98
Cidofovir‐induced end‐stage renal failure
Meier, P., Dautheville, S., Ronco, P. M., & Rossert, J. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.1.148 · Cited by 88
Secondary renal Fanconi syndrome caused by valproate therapy
Watanabe, T., Yoshikawa, H., Yamazaki, S., Abe, Y., & Abe, T. (2005) · Pediatric Nephrology · doi:10.1007/s00467-005-1827-7 · Cited by 70
Bhattacharyya, O. K., Shah, B. R., & Booth, G. L. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080554 · Cited by 60
Quimby, D. S., & Brito, M. O. (2005) · PubMed · Cited by 52
Kinai, E., & Hanabusa, H. (2005) · AIDS · doi:10.1097/01.aids.0000194130.05264.83 · Cited by 51
Abnormal urinary protein excretion in HIV-infected patients.
Kimmel, P. L., Umana, W. O., & Bosch, J. (1993) · PubMed · Cited by 48
Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
Jiménez‐Nácher, I., García, B., Barreiro, P., Rodríguez‐Nóvoa, S., Morelló, J., González‐Lahoz, J., de Mendoza, C., & Soriano, V. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn252 · Cited by 44
Self-citationEffect of tenofovir on renal glomerular and tubular function
Fux, C. A., Christen, A., Zgraggen, S., Mohaupt, M. G., & Furrer, H. (2007) · AIDS · doi:10.1097/qad.0b013e328216f15b · Cited by 42
Gérard, L., Chazallon, C., Taburet, A., Girard, P., Aboulker, J.-P., & Piketty, C. (2007) · Antiviral Therapy · doi:10.1177/135965350701200110 · Cited by 32
HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management
Atta, M. G., Lucas, G. M., & Fine, D. M. (2008) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.6.3.365 · Cited by 26
Causes and consequences of hypokalemia in patients on tenofovir disoproxil fumarate
Shepp, D. H., Curtis, S., & Rooney, J. F. (2007) · AIDS · doi:10.1097/qad.0b013e3280b07b6c · Cited by 18
Cited by
Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence
Hall, A. M., Hendry, B. M., Nitsch, D., & Connolly, J. O. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.01.022 · Cited by 373
Drug-Induced Acute Kidney Injury
Perazella, M. A., & Rosner, M. H. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11290821 · Cited by 357
Herlitz, L. C., Mohan, S., Stokes, M. B., Radhakrishnan, J., D'Agati, V. D., & Markowitz, G. S. (2010) · Kidney International · doi:10.1038/ki.2010.318 · Cited by 348
Lucas, G. M., Ross, M. J., Stock, P. G., Shlipak, M. G., Wyatt, C. M., Gupta, S. K., Atta, M. G., Wools-Kaloustian, K. K., Pham, P. A., Bruggeman, L. A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu617 · Cited by 310
Tenofovir Nephrotoxicity: 2011 Update
Fernandez-Fernandez, B., Montoya-Ferrer, A., Sanz, A. B., Sanchez-Niño, M. D., Izquierdo, M. C., Poveda, J., Sainz-Prestel, V., Ortiz-Martin, N., Parra-Rodriguez, A., Selgas, R., et al. (2011) · AIDS Research and Treatment · doi:10.1155/2011/354908 · Cited by 296
Metadata
- Authors
- Labarga, P., Barreiro, P., Martin-Carbonero, L., Rodriguez-Novoa, S., Solera, C., Medrano, J., Rivas, P., Albalater, M., Blanco, F., Moreno, V., Vispo, E., & Soriano, V.
- Venue
- AIDS
- Published
- 2009-03-27
- Volume
- 23
- Issue
- 6
- Pages
- 689-696
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2091989309
- Cited by
- 294
- References
- 33
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.